{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:24:30Z","timestamp":1793049870447,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Struct Mol Biol"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1038\/s41594-020-0405-9","type":"journal-article","created":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T12:04:26Z","timestamp":1586174666000},"page":"319-322","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":102,"title":["Crystal structure of the SALL4\u2013pomalidomide\u2013cereblon\u2013DDB1 complex"],"prefix":"10.1038","volume":"27","author":[{"given":"Mary E.","family":"Matyskiela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Clayton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinde","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Mayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbra","family":"Pagarigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Rolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence G.","family":"Hamann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6407-7344","authenticated-orcid":false,"given":"Philip P.","family":"Chamberlain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,6]]},"reference":[{"key":"405_CR1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1177\/1753193418805249","volume":"44","author":"N Vargesson","year":"2019","unstructured":"Vargesson, N. The teratogenic effects of thalidomide on limbs. J. Hand Surg. Eur. Vol. 44, 88\u201395 (2019).","journal-title":"J. Hand Surg. Eur. Vol."},{"key":"405_CR2","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/s41589-019-0362-y","volume":"15","author":"PP Chamberlain","year":"2019","unstructured":"Chamberlain, P. P. & Hamann, L. G. Development of targeted protein degradation therapeutics. Nat. Chem. Biol. 15, 937\u2013944 (2019).","journal-title":"Nat. Chem. Biol."},{"key":"405_CR3","doi-asserted-by":"crossref","unstructured":"Matyskiela, M. E. et al. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase. Nature 535, 252\u2013257 (2016).","DOI":"10.1038\/nature18611"},{"key":"405_CR4","doi-asserted-by":"crossref","unstructured":"Ito, T. et al. Identification of a primary target of thalidomide teratogenicity. Science 327, 1345\u20131350 (2010).","DOI":"10.1126\/science.1177319"},{"key":"405_CR5","doi-asserted-by":"crossref","unstructured":"Angers, S. et al. Molecular architecture and assembly of the DDB1\u2013CUL4A ubiquitin ligase machinery. Nature 443, 590\u2013593 (2006).","DOI":"10.1038\/nature05175"},{"key":"405_CR6","unstructured":"Chamberlain, P. P. et al. Structure of the human Cereblon\u2013DDB1\u2013lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat. Struct. Mol. Biol. 21, 803\u2013809 (2014)."},{"key":"405_CR7","doi-asserted-by":"crossref","unstructured":"Fischer, E. S. et al. Structure of the DDB1\u2013CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 512, 49\u201353 (2014).","DOI":"10.1038\/nature13527"},{"key":"405_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15398","volume":"8","author":"J An","year":"2017","unstructured":"An, J. et al. pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4(CRBN) ubiquitin ligase. Nat. Commun. 8, 15398 (2017).","journal-title":"Nat. Commun."},{"key":"405_CR9","doi-asserted-by":"crossref","unstructured":"Donovan, K. A., et al. Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. Elife 7, e38430 (2018).","DOI":"10.7554\/eLife.38430"},{"key":"405_CR10","doi-asserted-by":"crossref","unstructured":"Kronke, J. et al. Lenalidomide induces ubiquitination and degradation of CK1\u0251 in del(5q) MDS. Nature 523, 183\u2013188 (2015).","DOI":"10.1038\/nature14610"},{"key":"405_CR11","doi-asserted-by":"crossref","unstructured":"Kronke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301\u2013305 (2014).","DOI":"10.1126\/science.1244851"},{"key":"405_CR12","doi-asserted-by":"crossref","unstructured":"Lu, G. et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343, 305\u2013309 (2014).","DOI":"10.1126\/science.1244917"},{"key":"405_CR13","doi-asserted-by":"crossref","unstructured":"Petzold, G., Fischer, E. S. & Thoma, N. H. Structural basis of lenalidomide-induced CK1\u0251 degradation by the CRL4(CRBN) ubiquitin ligase. Nature 532, 127\u2013130 (2016).","DOI":"10.1038\/nature16979"},{"key":"405_CR14","doi-asserted-by":"crossref","unstructured":"Sievers, Q.L., et al. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science 362, eaat0572 (2018).","DOI":"10.1126\/science.aat0572"},{"key":"405_CR15","unstructured":"Gandhi, A. K. et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br. J. Haematol. 164, 811\u2013821 (2014)."},{"key":"405_CR16","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/s41589-018-0129-x","volume":"14","author":"ME Matyskiela","year":"2018","unstructured":"Matyskiela, M. E. et al. SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate. Nat. Chem. Biol. 14, 981\u2013987 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"405_CR17","doi-asserted-by":"crossref","unstructured":"Kohlhase, J. & Holmes, L. B. Mutations in SALL4 in malformed father and daughter postulated previously due to reflect mutagenesis by thalidomide. Birth Defects Res. A Clin. Mol. Teratol. 70, 550\u2013551 (2004).","DOI":"10.1002\/bdra.20050"},{"key":"405_CR18","unstructured":"Kohlhase, J. et al. Mutations at the SALL4 locus on chromosome 20 result in a range of clinically overlapping phenotypes, including Okihiro syndrome, Holt\u2013Oram syndrome, acro-renal-ocular syndrome, and patients previously reported to represent thalidomide embryopathy. J. Med. Genet. 40, 473\u2013478 (2003)."},{"key":"405_CR19","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1136\/jmg.2004.019901","volume":"41","author":"W Borozdin","year":"2004","unstructured":"Borozdin, W. et al. SALL4 deletions are a common cause of Okihiro and acro-renal-ocular syndromes and confirm haploinsufficiency as the pathogenic mechanism. J. Med. Genet. 41, e113 (2004).","journal-title":"J. Med. Genet."},{"key":"405_CR20","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1038\/s41589-019-0366-7","volume":"15","author":"T Asatsuma-Okumura","year":"2019","unstructured":"Asatsuma-Okumura, T. et al. p63 is a cereblon substrate involved in thalidomide teratogenicity. Nat. Chem. Biol. 15, 1077\u20131084 (2019).","journal-title":"Nat. Chem. Biol."},{"key":"405_CR21","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658\u2013674 (2007).","journal-title":"J. Appl. Crystallogr."},{"key":"405_CR22","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P. et al. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"405_CR23","doi-asserted-by":"crossref","unstructured":"Murshudov, G. N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D Biol. Crystallogr. 67, 355\u2013367 (2011).","DOI":"10.1107\/S0907444911001314"},{"key":"405_CR24","unstructured":"Harder, E. et al. OPLS3: a force field providing broad coverage of drug-like small molecules and proteins. J. Chem. Theory Comput. 12, 281\u2013296 (2016)."},{"key":"405_CR25","doi-asserted-by":"crossref","unstructured":"Humphrey, W., Dalke, A. & Schulten, K. VMD: visual molecular dynamics. J. Mol. Graph. 14, 33\u201338 (1996).","DOI":"10.1016\/0263-7855(96)00018-5"}],"container-title":["Nature Structural & Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41594-020-0405-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41594-020-0405-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41594-020-0405-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:26:14Z","timestamp":1684607174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41594-020-0405-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["405"],"URL":"https:\/\/doi.org\/10.1038\/s41594-020-0405-9","relation":{},"ISSN":["1545-9993","1545-9985"],"issn-type":[{"value":"1545-9993","type":"print"},{"value":"1545-9985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"25 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors are, or have been, employees or contractors of Celgene and\/or Bristol-Myers Squibb.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}